Repare Therapeutics
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7171 Frederick-Banting Building 2 Ste 27...Phone Number
(857) 412-7018Website
www.reparerx.comRevenue
$11.9 MillionStock Symbol
RPTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Repare Therapeutics
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.Explore more
Repare Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Repare Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Repare Therapeutics recently announced quarterly report
Repare Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Repare Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Repare Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Repare Therapeutics
Check if Repare Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Repare Therapeutics launches new products
Check out if Repare Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Repare Therapeutics
Compare insights from companies similar to Repare Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Repare Therapeutics
$11.9M
51-200
Public
$150.5M
2016
JO
Joseph O'ConnellExecutive VP, Clinical Development & Medical Affairs
Company Profile Activity
Activity Insights
Repare Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Repare Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Repare Therapeutics.
Repare Therapeutics financials insights
Gather financial insights about Repare Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$68M
2019
Series B
$82.5M
Repare Therapeutics Tech Stack
A closer look at the technologies used by Repare Therapeutics
Most Recent Scoops
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Product Development, Research & Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals, Contracts
Person-Based
Earnings
Earnings, Finance
Repare Therapeutics News & Media
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Repare Therapeutics Inc. (NASDAQ: RPTX) related to its sale to XenoTherapeutics, Inc. Upon closing of theRepare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
CAMBRIDGE, Mass. & MONTREAL, November 14, 2025--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, "Xeno"), a non-profit biotechnology company, pursuant to which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of Repare (the "CoShareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc. Click here to learn how to join our investigation and obtain...Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. (“Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inh
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Repare Therapeutics
Sign Up For FreeTo access detailed company insights
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic i... Read More
